The financial ramifications of Pfizer’s revenue decline due to the COVID-19 pandemic are now revealing their human toll as the company embarks on a substantial $3.5 billion cost-saving effort. The latest move involves a significant workforce reduction, with Pfizer announcing the layoff of 791 employees in Gladstone, New Jersey, as indicated in a Worker Adjustment and Retraining Notification (WARN) alert from the state.
This downsizing may not be the final chapter, however. Pfizer recently announced its intention to initiate an “enterprise-wide cost realignment program” after revising its 2023 revenue projection downward by $9 billion. The extensive job cuts in New Jersey are slated to take effect in February 2024, according to the local WARN notice.
Also Read: BMS Layoffs Over 100 Employees Lose Jobs After Earnings Miss
While Pfizer has not responded immediately to inquiries about these layoffs, the pharmaceutical giant’s actions are in response to financial challenges. Earlier this month, the company made significant adjustments to its 2023 revenue forecast and initiated a comprehensive cost-cutting campaign. Out of the $3.5 billion in planned cuts by the end of the next year, Pfizer aims to achieve $1 billion in savings in 2023.
This reduction in workforce is not an isolated event, as Pfizer has previously implemented similar measures in other locations. Notably, the company disclosed 69 layoffs in Illinois over the summer and, more recently, carried out undisclosed layoffs of Pfizer employees in Boulder, Colorado, in early October. Additionally, Pfizer has announced the closure of two facilities in North Carolina.
Also Read: September Layoffs: A Recap Of Recent Workforce Reductions In Biotech And Pharma
Criticism from Pfizer’s staff has also arisen regarding the job cuts and the company’s communication around the cost-saving plan. Reports suggest that employees have expressed dissatisfaction with the “casual” tone and demeanor of executives during the announcement of these reductions.
As Pfizer navigates these challenging financial circumstances, it remains to be seen how the company will address both its fiscal goals and its employees’ concerns. The impact of these cost-cutting measures on the pharmaceutical giant’s future and its workforce will be closely monitored.
